exosomes

A newly shared guide walks investors through evaluating healthcare AI investments, laying out an evidence route map for judging claims in the sector. It also covers 'exosomes', described as a case of hype outpacing the underlying science, framed as a warning about how far medical technology narratives can run ahead of clinical proof.